Japanese Study of Ipilimumab Administered in Combination With Paclitaxel/Carboplatin in Patients With Nonsmall-cell Lung Cancer
2014년 6월 23일 업데이트: Bristol-Myers Squibb
Phase 1 Study of Ipilimumab (BMS-734016) in Combination With Paclitaxel and Carboplatin in Japanese Patients With Non-Small Cell Lung Cancer
The primary purpose of this study was to establish the recommended dose of ipilimumab administered in combination with paclitaxel and carboplatin in Japanese patients with nonsmall-cell lung cancer.
연구 개요
상태
완전한
정황
연구 유형
중재적
등록 (실제)
15
단계
- 1단계
연락처 및 위치
이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.
연구 장소
-
-
Tokyo
-
Chuo-ku, Tokyo, 일본, 1040045
- Local Institution
-
-
참여기준
연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.
자격 기준
공부할 수 있는 나이
16년 이상 (성인, 고령자)
건강한 자원 봉사자를 받아들입니다
아니
연구 대상 성별
모두
설명
Key Inclusion Criteria:
- Histologically or cytologically documented nonsmall-cell lung cancer (NSCLC) presenting as stage IIIB disease without indications for definitive radiotherapy, stage IV disease, or recurrent disease following radiation therapy or surgical resection
- No prior chemotherapy, hormonal therapy, immunotherapy, or targeted-therapy-containing regimens for the treatment of NSCLC
- Life expectancy of at least 3 months
- Eastern Cooperative Oncology Group performance score of 0-1
- Adequate bone marrow function
- Hemoglobin ≥9.0 g/dL
- Absolute neutrophil count ≥1,500/mm^3
- Platelet count ≥100,000/mm^3
- Adequate liver function
- Total bilirubin level ≤2.0*the upper limit of normal (ULN)
- Asparate aminotransferase level ≤2.5*ULN
- Alanine aminotransferase level ≤2.5*ULN
- Adequate renal function
- Calculated creatinine clearance based on Cockcroft and Gault formula ≥50 mL/min.
Key Exclusion Criteria:
- Symptomatic central nervous system (CNS) metastasis or active CNS metastasis requiring medication
- Malignant body cavity fluid (eg, pleural effusion, cardiac effusion, ascites) that recurred despite appropriate supportive care
- Prior radiation of ≥30% of major bone-marrow containing areas (pelvis, lumbar spine)
- Documented history of severe autoimmune or immune-mediated symptomatic disease that required prolonged (longer than 2 months) systemic immunosuppressant treatment
- Documented history of motor neuropathy considered of autoimmune origin (eg, Guillain Barré syndrome)
- Any concurrent malignancy other than nonmelanoma skin cancer, carcinoma in situ of the cervix, carcinoma in situ of the breast, carcinoma of the mucous membrane of the gastrointestinal tract, or superficial bladder cancer treated with systemic therapy
- ≥Grade 2 diarrhea
- History of or concurrent disease of gastrointestinal tract perforations
- ≥Grade 2 peripheral neuropathy (motor or sensory)
- Uncontrolled intercurrent illness including infection requiring systemic therapy, symptomatic congestive heart failure, uncontrolled hypertension, uncontrolled angina pectoris, uncontrolled peptic ulcer, and cardiac arrhythmia requiring medication
- Positive finding for human immunodeficiency virus antibody, hepatitis B surface antigen, or hepatitis C virus antibody.
공부 계획
이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위화되지 않음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Dose Level 1: Ipilimumab, 3 mg/kg + Paclitaxel + Carboplatin
Participants received ipilimumab, 3 mg/kg, administered as a single dose intravenously (IV) over 90 minutes every 3 weeks, plus paclitaxel, 175 mg/m^2 , administered as a single dose IV over 3 hours every 3 weeks (up to 6 doses), and carboplatin, area under the curve (AUC)=6, administered as a single dose IV over 30-60 minutes every 3 weeks (up to 6 doses).
|
Intervenous (IV) injection, administered every 3 weeks for up to 6 cycles
IV injection, 175 mg/m^2, administered every 3 weeks for up to 6 cycles
IV injection, AUC=6, administered every 3 weeks for up to 6 cycles.
(AUC=area under the concentration curve)
|
|
실험적: Dose Level 2: Ipilimumab, 10 mg/kg + Paclitaxel + Carboplatin
Participants received ipilimumab, 10 mg/kg, administered as a single dose IV over 90 minutes every 3 weeks, plus paclitaxel, 175 mg/m^2 , administered as a single dose IV over 3 hours every 3 weeks (up to 6 doses), and carboplatin, AUC=6, administered as a single dose IV over 30-60 minutes every 3 weeks (up to 6 doses).
|
IV injection, 175 mg/m^2, administered every 3 weeks for up to 6 cycles
IV injection, AUC=6, administered every 3 weeks for up to 6 cycles.
(AUC=area under the concentration curve)
IV injection, administered every 3 weeks for up to 6 cycles
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Number of Participants Experiencing a Dose-limiting Toxicity (DLT)
기간: Day 1 of Cycles 1 and 2 From Day 1 of Cycle 3 to Day 21 of Cycle 4
|
A DLT was defined as study drug-related adverse event occurring during the first 2 cycles after ipilimumab administration in the induction phase and was any of the following: Grade 4 absolute neutrophil count (ANC) decreased (<500 cells/ mm^3) for 7 or more consecutive days; febrile Neutropenia (body temperature ≥38.5°
C with ANC <1000 /mm^3) lasting >3 days; Grade 4 platelet count decreased (<25,000 cells/mm^3) or Grade 3 platelet count decreased requiring a platelet transfusion; Grade 3 or greater nausea, vomiting, diarrhea, despite the use of adequate/maximal medical intervention; Grade 3 or greater aspartate transaminase/alanine transaminase level and rash that has not resolved to Grade 2 or lower within 2 weeks after onset; or any Grade 3 or greater nonhematologic toxicity (except Grade 3 fatigue, Grade 3 asthenia, Grade 3 transient arthralgia/myalgia, or Grade 3 transient abnormal electrolyte levels).
|
Day 1 of Cycles 1 and 2 From Day 1 of Cycle 3 to Day 21 of Cycle 4
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Number of Participants With Death As Outcome, Serious Adverse Events (SAEs), Drug-related SAEs, Drug-related Adverse Events (AEs), AEs Leading to Discontinuation, Drug-related AEs Leading to Discontinuation
기간: Continuously from Day 1 to Week 24 and every12 weeks thereafter during maintenance until discontinuation of drug
|
AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment.
SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization.
Treatment-related=having certain, probable, possible, or unknown relationship to study drug.
AE incidence was assessed from Day 1 until Week 24 and every 12 weeks thereafter during the maintenance period, until discontinuation of study drug, due to progression of disease, toxicities requiring discontinuation, withdrawal of consent, or study closure, and at least every 4 weeks(±1 week) until all study drug-related toxicities had recovered to resolved, stabilized or returned to baseline or were deemed irreversible during the follow-up period).
|
Continuously from Day 1 to Week 24 and every12 weeks thereafter during maintenance until discontinuation of drug
|
|
Number of Participants With Best Overall Response (BOR) of Partial Response (PR) or Stable Disease
기간: Day 1 of Cycle 3, Day 1 of Cycle 5, and Day 22 of Cycle 6
|
Tumor response was determined for all participants with measurable lesions by radiologic responses as defined by Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1.
The BOR was the best response recorded from start of treatment until disease progression/recurrence.
RECIST for target lesions: PR=at least a 30% decrease in the sum of the longest dimension (LD) of target lesions, taking as reference the baseline sum LD; stable disease=neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease, taking as reference the smallest sum LD since the treatment started.
At minimum, tumor measurements were to be obtained at screening, every 6 weeks (±1 week) during the induction phase and every 12 weeks (±1 week) during the maintenance phase.
|
Day 1 of Cycle 3, Day 1 of Cycle 5, and Day 22 of Cycle 6
|
|
Maximum Serum Concentration (Cmax) of Ipilimumab
기간: During Cycle 3: predose and 1.5, 4, 24, 48, 168, and 336 hours postdose ipilimumab
|
Cmax was recorded directly from experimental observations.
Actual times were used for the analyses.
Cmax measurements were performed during the 3rd cycle; at predose and at 1.5, 4 , 24 (Day 2), 48 (Day 3), 168 hrs (Day 8),and 336 (Day 15) hours postdose; during the 4th and subsequent cycle, predose ipilimumab; and off-treatment until progression of disease, toxicities requiring discontinuation, withdrawal of consent, or study closure.
|
During Cycle 3: predose and 1.5, 4, 24, 48, 168, and 336 hours postdose ipilimumab
|
|
Trough Observed Serum Concentration (Cmin) of Ipilimumab
기간: During Cycle 3: predose and 1.5, 4, 24, 48, 168, and 336 hours postdose ipilimumab
|
Cmin was recorded directly from experimental observations.
Actual times were used for the analyses.
Cmin measurements were performed during the 3rd cycle, at predose and at 1.5, 4 , 24 (Day 2), 48 (Day 3), 168 (Day 8), and 336 (Day 15) hours postdose; during the 4th and subsequent cycle, predose ipilimumab; and off-treatment until progression of disease, toxicities requiring discontinuation, withdrawal of consent; or study closure.
|
During Cycle 3: predose and 1.5, 4, 24, 48, 168, and 336 hours postdose ipilimumab
|
|
Area Under the Concentration Curve From Time 0 to Day 21 (in 1 Interval Dosing) (AUC[0-21d]) for Ipilimumab
기간: During Cycle 3: predose and 1.5, 4, 24, 48, 168, and 336 hours postdose ipilimumab
|
The AUC(0-21d) was calculated using a mixture of log- and linear-trapezoidal summations.
Using no weighting factor, the terminal log-liner phase of the concentration-time curve was determined by least-square linear regression of at least 3 data points.
Individual patient pharmacokinetic (PK) parameter values were derived by noncompartmental methods using a validated PK analysis program.
Actual times were used for the analyses.
AUC(0-21d) measurements were performed during the 3rd cycle, at predose and at 1.5, 4 , 24 (Day 2), 48 (Day 3), 168 hrs (Day 8),and 336 (Day 15) hours postdose; during the 4th and subsequent cycle, predose ipilimumab; and off-treatment until progression of disease, toxicities requiring discontinuation, withdrawal of consent; or study closure.
|
During Cycle 3: predose and 1.5, 4, 24, 48, 168, and 336 hours postdose ipilimumab
|
|
Time of Maximum Observed Serum Concentration (Tmax)
기간: During Cycle 3: predose and 1.5, 4, 24, 48, 168, and 336 hours postdose ipilimumab
|
Tmax was recorded directly from experimental observations.
Actual times were used for the analyses.
Tmax measurements were performed during the 3rd cycle; at predose and at 1.5, 4 , 24 (Day 2), 48 (Day 3), 168 hrs (Day 8),and 336 (Day 15) hours postdose; during the 4th and subsequent cycle, predose ipilimumab; and off-treatment until progression of disease, toxicities requiring discontinuation, withdrawal of consent, or study closure.
|
During Cycle 3: predose and 1.5, 4, 24, 48, 168, and 336 hours postdose ipilimumab
|
|
Serum Half-life (T-HALF) of Ipilimumab
기간: During Cycle 3: predose and 1.5, 4, 24, 48, 168, and 336 hours postdose ipilimumab
|
T-HALF was calculated as the ratio of ln(2) to elimination rate constant (K), where K was estimated as negative slope obtained by regression of the terminal log-linear portion of the serum concentration vs time profile following the ipilimumab dose on Day 1 of Cycle 3. Individual patient pharmacokinetic (PK) parameter values were derived by noncompartmental methods, using a validated PK analysis program.
Actual times were used for the analyses.
T-HALF measurements were performed during the 3rd cycle; at predose and at 1.5, 4 , 24 (Day 2), 48 (Day 3), 168 hrs (Day 8),and 336 (Day 15) hours postdose; during the 4th and subsequent cycle, predose ipilimumab; and off-treatment until progression of disease, toxicities requiring discontinuation, withdrawal of consent, or study closure.
|
During Cycle 3: predose and 1.5, 4, 24, 48, 168, and 336 hours postdose ipilimumab
|
공동 작업자 및 조사자
여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.
간행물 및 유용한 링크
연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.
연구 기록 날짜
이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.
연구 주요 날짜
연구 시작
2010년 9월 1일
기본 완료 (실제)
2013년 6월 1일
연구 완료 (실제)
2013년 6월 1일
연구 등록 날짜
최초 제출
2010년 7월 16일
QC 기준을 충족하는 최초 제출
2010년 7월 16일
처음 게시됨 (추정)
2010년 7월 19일
연구 기록 업데이트
마지막 업데이트 게시됨 (추정)
2014년 7월 22일
QC 기준을 충족하는 마지막 업데이트 제출
2014년 6월 23일
마지막으로 확인됨
2014년 6월 1일
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .